{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:23:15Z","timestamp":1788355395404,"version":"build-2803163510"},"reference-count":52,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Gastroenterology & Hepatology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1586\/egh.09.20","type":"journal-article","created":{"date-parts":[[2009,7,9]],"date-time":"2009-07-09T08:31:17Z","timestamp":1247128277000},"page":"235-248","source":"Crossref","is-referenced-by-count":16,"title":["Selecting appropriate anti-TNF agents in inflammatory bowel disease"],"prefix":"10.1586","volume":"3","author":[{"given":"Laura","family":"Yun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2005.08.011"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.014"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"CIT0008","unstructured":"Feagan B, Panaccione R, Sandborn WJ, D\u2019haens GR, Schreiber S, Rutgeerts PJ. An evaluation of adalimumab on the risk of hospitalization in patients with Crohn\u2019s disease, data from CHARM. Presented at:Digestive Disease Week, WA, USA, 19\u201324 May 2007."},{"key":"CIT0009","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Kamm MA, Panaccione Ret al.Steroid-free remission over 2 years in Crohn\u2019s patients receiving adalimumab: the open label extension of the CHARM Trial. Presented at:Digestive Disease Week.San Diego, CA, USA, 17\u201322 May 2008.","DOI":"10.1016\/S0016-5085(08)62290-8"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/j.1572-0241.2003.07674.x","volume":"98","author":"Feagan","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.03.002"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200207000-00001","volume":"8","author":"Lichtenstein","year":"2002","journal-title":"Inflamm. Bowel Dis."},{"key":"CIT0013","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Kamm MA, Colombel JF. Sustained steroid-free clinical remission in patients with moderate to severe Crohn\u2019s disease treated with adalimumab. Presented at:ACG Annual Scientific Meeting.Las Vegas, NV, USA, 20\u201325 October 2006.","DOI":"10.14309\/00000434-200609001-01181"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.18160"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.51.1.289"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20225"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"CIT0022","unstructured":"Rutgeerts PJ, Melilli LE, Li J, Pollack PF. Adalimumab maintains improvement in Inflammatory Bowel Disease Questionnaire scores over 1 year following the initial attainment of remission in patients with moderately to severely active Crohn\u2019s disease: results of the CLASSIC II study. Presented at:Digestive Disease Week. Los Angeles, CA, USA, 20\u201325 May 2006."},{"key":"CIT0023","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan BG, Stoinov Set al.Certolizumab pegol for the treatment of Crohn\u2019s disease.N. Engl. J. Med.357(3), 228\u2013238 (2007).","DOI":"10.1056\/NEJMoa067594"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.064"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"CIT0027","doi-asserted-by":"crossref","unstructured":"Schwartz DA, Loftus EV, Tremaine WJet al.The natural history of fistulizing Crohn\u2019s disease in Olmsted County, Minnesota.Gastroenterology122(4), 875\u2013880 (2002).","DOI":"10.1053\/gast.2002.32362"},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/gut.21.6.525","volume":"21","author":"Hellers","year":"1980","journal-title":"Gut"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"CIT0031","doi-asserted-by":"crossref","unstructured":"Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn\u2019s disease.Gastroenterology128(4), 862\u2013869 (2005).","DOI":"10.1053\/j.gastro.2005.01.048"},{"key":"CIT0033","unstructured":"Jarnerot G, Hertervig E, Friis-Liby Iet al.Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.Gastroenterology128(7), 1805\u20131811 (2005)."},{"key":"CIT0035","doi-asserted-by":"crossref","unstructured":"Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis.J. Clin. Gastroenterol.40(6), 476\u2013481 (2006).","DOI":"10.1097\/00004836-200607000-00004"},{"key":"CIT0036","doi-asserted-by":"crossref","unstructured":"Lees CW, Heys D, Ho GTet al.A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.Aliment. Pharmacol. Ther.26(3), 411\u2013419 (2007).","DOI":"10.1111\/j.1365-2036.2007.03383.x"},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1365-2036.2007.03300.x","volume":"25","author":"Jakobovits","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"CIT0038","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2036.2007.03415.x","volume":"26","author":"Kohn","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60751-X"},{"key":"CIT0041","doi-asserted-by":"crossref","unstructured":"Vermeire S, Abreu M, D\u2019 Haens Get al.Efficacy and safety of certolizumab pegol in patients with active Crohn\u2019s disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the WELCOME study. Presented at:Digestive Disease Week.San Diego, CA, USA, 17\u201322 May 2008.","DOI":"10.1097\/00054725-200812003-00101"},{"key":"CIT0042","doi-asserted-by":"crossref","unstructured":"Hanauer SB, D Haens GR, Colombel JFet al.Sustained clinical remission in patients with moderate to severe Crohn\u2019s disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressive therapy. Presented at:ACG Annual Scientific Meeting.Las Vegas, NV, USA, 20\u201325 October 2006.","DOI":"10.14309\/00000434-200609001-01173"},{"key":"CIT0044","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.World J. Gastroenterol.13(16), 2328\u20132332 (2007).","DOI":"10.3748\/wjg.v13.i16.2328"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03811.x"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.03.014"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31802f6424"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"CIT0050","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.gastro.2008.05.061","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"CIT0051","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Rutgeerts P, Reinisch Wet al.Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn\u2019s disease naive to immunomodulators and biologic therapy. Presented at:ACG Annual Scientific Meeting.Orlando, FL, USA, 3\u20138 October 2008.","DOI":"10.1002\/ibd.20829"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.012"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20169"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.003"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.18144"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60304-9"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.5.674"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502023320503"},{"key":"CIT0059","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"}],"container-title":["Expert Review of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/egh.09.20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T10:42:43Z","timestamp":1589971363000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/egh.09.20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1586\/egh.09.20"],"URL":"https:\/\/doi.org\/10.1586\/egh.09.20","relation":{},"ISSN":["1747-4124","1747-4132"],"issn-type":[{"value":"1747-4124","type":"print"},{"value":"1747-4132","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}